Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

LATE-BREAKING RESEARCH: Practice Management Research
Abstract #LB04

Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts, Breast Cancer

Presenter: Fangzheng Yuan, PharmD, BCPS, Clinical Pharmacy Specialist, Baptist Hospitals of Southeast Texas

Co-Authors: Ahmed Abdelhakeem, MD, Baptist Hospitals of Southeast Texas; Samantha Blevins, RN, Baptist Hospitals of Southeast Texas; Chelsey Peters, RN, OSN, Baptist Hospitals of Southeast Texas; Susan Whalen, BSN, CTR, Baptist Hospitals of Southeast Texas; Ernest Hymel, MD, PhD, Baptist Regional Cancer Network

BACKGROUND: Delays in breast cancer treatment have been associated with increased mortality.1 The COVID-19 pandemic has posed prolonged and significant stress on healthcare resources, which may have affected the quality and outcomes of breast cancer care.2

OBJECTIVE: To compare the time to treatment initiation (TTI) and outcomes in patients with nonmetastatic breast cancer before and during the COVID-19 pandemic.

METHOD: This retrospective study included adult patients with newly diagnosed nonmetastatic breast cancer at 2 community cancer centers of the Baptist Regional Cancer Network (BRCN) in Southeast Texas. Patients diagnosed between January 2018 and June 2019 were included in the control group. Patients diagnosed between April 2020 and September 2021 were included in the COVID-19 group. Patients were excluded if they received initial treatment outside of the BRCN network or for palliative intent. The primary outcome was TTI, defined as time from histologic diagnosis to treatment initiation. The primary analysis was done by t-test. The study had 80% power to detect an absolute increase of 10 days in TTI using a 2-sided alpha of 0.05.

RESULTS: The study included 156 patients—87 patients in the control group and 69 in the COVID-19 group. The median follow-up periods were 37 months (IQR, 32-40 months) in the control group and 8 months (IQR, 6-14 months) in the COVID-19 group. No significant difference in TTI was observed between the control (48.3 days) and the COVID-19 (47.7 days) groups (absolute difference, 0.7; 95% confidence interval, 8.6-10.0; P = .88). After adjusting for initial treatment modality, histology, and clinical stage, the TTI remained similar between the control group and the COVID-19 group (P = .92). No association was noted between the TTI and the number of new COVID-19 cases in the county in the COVID-19 group (P = .85). The proportion of patients diagnosed at disease stage II or III was higher in the COVID-19 group (52.2%) compared with the control group (42.3%), although this was not statistically significant (P = .23). Breast-conserving surgery was done in 26.5% (9/34) of the control group and 55% (11/20) of the COVID-19 group among patients who completed neoadjuvant systemic therapy and surgeries (P = .04). Pathologic complete response was achieved in 58.3% (7/12) of the control group and 14% (1/7) of the COVID-19 group among patients with triple-negative or HER2-positive breast cancer who completed neoadjuvant systemic therapy and surgeries. Overall survival rates at 1 year were 89.7% (78/87) in the control group and 100% (25/25) in the COVID-19 group among patients who reached 1 year after diagnosis (P = .09).

DISCUSSION: No significant delay in breast cancer treatment initiation was observed during the COVID-19 pandemic. Although preliminary outcomes were similar before and during the COVID-19 pandemic, further assessment of the long-term impact of COVID-19 on breast cancer outcomes is needed.

  1. Cone EB, Marchese M, Paciotti M, et al. Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers. JAMA Netw Open. 2020;3:e2030072. doi: 10.1001/jamanetworkopen.2020.30072.
  2. Bartlett DL, Howe JR, Chang G, et al. Management of cancer surgery cases during the COVID-19 pandemic: considerations. Ann Surg Oncol. 2020;27:1717-1720.
Related Items
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.